SEC Form 4 · accession 0001209191-17-041070
ALBIREO PHARMA, INC. · ALBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Davey Scoon
Director
Period of report
Jun 16, 2017
Accepted (ET)
Jun 20, 2017 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001322505
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.05 | Jun 16, 2017 | A | 3,000 | A | — | Jun 15, 2027 | Common Stock | 3,000 | 3,000 | D |
Explanation of responses
- F1This option will vest and become exercisable in full on the earlier of (i) June 16, 2018 or (ii) the day prior to the issuer's 2018 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date.